Editorial: Bladder tumor markers, intravesical therapy and systemic chemotherapy

Journal of Urology

Volumn 166, Issue 2, 2001, Pages 488-489

  Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKERATIN 18; CYTOKERATIN 8; EPIRUBICIN; ISONIAZID; TUMOR MARKER; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CYSTITIS; CYSTOSCOPY; EDITORIAL; HUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINE CYTOLOGY; CELL CULTURE; INTRAVESICAL DRUG ADMINISTRATION; NOTE;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; DEOXYCYTIDINE; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0034942882     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65968-X     Document Type: Editorial

References (9)

1. Transitional cell carcinoma of the prostate
2. Current bladder tumor tests: Does their projected utility fulfill clinical necessity?
3. De novo muscle invasive bladder cancer: Is there a change in trend?
4. Effect of chemotherapeutic agents on bladder cancer: A new animal model
5. Single and combination chemotherapy for primary murine bladder cancer
6. Cisdichlorodiammineplatinum(II) in advanced bladder cancer
7. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium
8. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
9. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer